Find a Clinical Trial

Showing 31 - 40 of 174 Trials

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT06671912

Population:

Adult

Phase:

III

This study is being done to answer the following question: Is treatment with a lower dose of tamoxifen, a form of hormonal therapy, as good as the usual hormonal therapy in women with low-risk, early-stage breast cancer? The usual approach for patients who are not in a study is treatment with hormonal therapy. Hormonal therapy can be an aromatase inhibitor (such as letrozole, anastrozole, or exemestane) or tamoxifen at a dose of 20mg/day. Your doctor can explain which treatment may be best for you. For patients who get the usual approach for this cancer, about 96 out of 100 are free of cancer...
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Principal Investigator:

Meghna S Trivedi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05812807

Population:

Adult

Phase:

III

This study is being done to answer the following question: Among patients with early-stage triple-negative breast cancer (TNBC) who achieve a pathologic complete response (pCR) after preoperative chemotherapy in combination with pembrolizumab, will observation after surgery be as effective as completing 6 more months of pembrolizumab after surgery at preventing cancer from coming back? This study aims to find out if observation is as good as the usual approach for early-stage TNBC. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab...
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged

Principal Investigator:

Joseph G. Jurcic, MD

Contact Number:

212-342-5162

NCT Number:

NCT07007312

Population:

Adult

Phase:

III

The purpose of this study is to evaluate an investigational drug called ziftomenib when added to either non-intensive chemotherapy (venetoclax and azacitidine) or intensive chemotherapy (cytarabine and daunorubicin), followed by ziftomenib maintenance therapy. Investigational means that ziftomenib has not been approved by the Food and Drug Administration (FDA) for use outside of research studies. Maintenance therapy refers to ongoing treatment given after the initial therapy to help keep the cancer from returning. Ziftomenib is being studied as a possible treatment for acute myeloid leukemia...
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab inCombination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary TractCancer (ARTEMIDE-Biliary02)

Principal Investigator:

Aiwu R He, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07221253

Population:

Adult

Phase:

III

The purpose of this study is to understand the effectiveness and safety of rilvegostomig in combination with chemotherapy to that of standard treatment for advanced biliary tract cancer (durvalumab in combination with gemcitabine and cisplatin). We are also performing this study to better understand advanced biliary tract cancer and associated health problems. Rilvegostomig has not been approved by the Food and Drug Administration (FDA). Durvalumab, gemcitabine, and cisplatin are FDA approved to treat biliary tract cancer, but the combination of rilvegostomig, gemcitabine, and cisplatin is...
Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

Principal Investigator:

Stephanie Smith-Marrone, MD

Contact Number:

212-342-5162

NCT Number:

NCT06632327

Population:

Adult

Phase:

III

The purpose of this study is to compare two usual treatment approaches using approved drugs before and after surgery or only after the surgery to find out which approach is better. The study doctors will decide which approach is better by determining which study group was less likely to have their lung cancer grow or spread. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? - Have you been diagnosed with early-stage Non-Small Cell Lung Cancer, which your doctor thinks can be treated with surgery? - Are you able to come to clinic for regularly scheduled treatment and...
RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY

Principal Investigator:

Melissa Accordino, MD

Contact Number:

212-342-5162

NCT Number:

NCT05642611

Population:

Adult

Phase:

III

The purpose of this study is to learn which of the following 3 study approaches is the most helpful to prevent peripheral neuropathy caused by taxane chemotherapy. These approaches will use a study device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress your arms and legs. The study will test which of the following combinations of cooling and/or compression to your arms and legs is better at preventing peripheral neuropathy: • Cryocompression (cooling plus moderate and low pressure to your arms and legs) • Continuous compression (moderate,...
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized,2-Arm Study of Adjuvant Daraxonrasib versus Standard of CareObservation Following Completion of Neoadjuvant and/orAdjuvant Chemotherapy in Patients with Resected PancreaticDuctal Adenocarcinoma

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07252232

Population:

Adult

Phase:

III

The purpose of this study is to test an experimental drug called Daraxonrasib (RMC-6236) compared to standard of care observation after finishinged chemotherapy given either before surgery to shrink the tumor (neoadjuvant chemotherapy) or after surgery to kill remaining cancer cells in patients with resected PDAC. Daraxonsrasib (RMC-6236) is not approved by the United States Food and Drug Administration (FDA). People who usually have this type of cancer typically receive surgery followed by chemotherapy, and then are monitored without additional treatment. This study is different because it...
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

Principal Investigator:

Alissa Michel, MD

Contact Number:

212-342-5162

NCT Number:

NCT06876714

Population:

Adult

Phase:

III

The purpose of this study is to compare the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2- targeted medications at reducing the risk of breast cancer coming back or death in patients with early-stage HER2+ breast cancer who had a pathologic complete response (pCR) after preoperative chemotherapy combined with trastuzumab. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if...
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (CCTG MA.39)

Principal Investigator:

Eileen Patricia Connolly, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT03488693

Population:

Adult

Phase:

III

The purpose of this study is to compare any good and bad effects of not giving regional radiotherapy to using regional radiotherapy. This study will help researchers learn if not giving regional radiotherapy is just as good as using regional radiotherapy. To be better, the approach of not giving regional radiotherapy should keep your breast cancer from coming back as good as giving regional radiotherapy. There will be about 2140 people taking part in this study. Are you Eligible? (Inclusion Criteria) To be eligible for this study, subjects must: 1. be ≥ 40 years of age. 2. have been...
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT06513962

Population:

Pediatrics/Adult

Phase:

III

Reproductive health outcomes, including the possibility of infertility from cancer treatment, are a major source of distress for adolescent and young adult (AYA) patients from diagnosis through survivorship. The overarching objective of this study is to investigate the impact of the Gonadotropin Releasing Hormone agonist (GnRHa) triptorelin, as a randomized intervention, on the ovarian reserve of newly diagnosed AYA cancer patients (exclusive of breast cancer) treated with alkylating agent chemotherapy. This trial is supported by the NCI Community Oncology Research Program (NCORP), led by the...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages